The FDA had a fairly quiet week, approving drugs, providing clearance, greenlighting clinical trials, and other regulatory activities for Alnylam, Eli Lilly, Cytokinetics, Prometheus, Owlet, and more.

Here’s a look at the agency’s reported activities.

Four more biotechs and a SPAC led by Bristol Myers Squibb vet Matthew Roden have priced IPOs, closing out another busy week on Wall Street.

Together, Praxis Precision Medicines, Tarsus Pharmaceuticals, Aligos Therapeutics, Kiromic BioPharma and Turmeric Acquisition — MPM’s blank check company — have raised $528 million on their public debuts.

Four more US biotechs filed to go public Friday as yet more companies clamber to get through a yawning IPO window and onto a market that’s signaled its willingness to reward nearly any new drugmaker.